HighRes Biosolutions and Novo Nordisk partner to transform drug discovery in automated Lab of the Future
HighRes Biosolutions and Novo Nordisk A/S today announced that they will collaborate to design a state-of-the-art robotic platform for high-throughput biologics engineering and characterisation. The integration of a multi-system robotics platform with sophisticated software control architecture will enable a digital transformation and accelerated discovery for Novo Nordisk’s peptide and large molecule therapeutics research.
“In order to maintain our leadership within biologics engineering we are investing in a fully automated and digital design platform. This investment is linked to our build-up in AI and advanced analytics and demonstrates Novo Nordisk’s commitment as a world leading biologics research company,” said Lars Fogh Iversen, senior vice president, Global Research Technologies, Novo Nordisk.
The platform will comprise several highly automated and integrated cells for production, characterisation and functional analysis of thousands of biologic compounds every month. Its scope covers the full range from small synthetic peptides to recombinantly expressed large proteins and will also include chemical modification of the molecules. The ambition is to build a system that is fully integrated with a modern data infrastructure and the data science and machine learning capabilities in Novo Nordisk.
Ira Hoffman, CEO of HighRes Biosolutions, said: “We are very excited to be working with Novo Nordisk on their Lab of the Future. We believe that the combination of our capabilities, products and vision make us the ideal partner for their digital transformation.”
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,200 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
About HighRes Biosolutions
HighRes Biosolutions improves human health through life science robotics. The company designs and builds innovative laboratory automation systems, dynamic scheduling software, and lab automation instruments that accelerate and streamline discovery. HighRes offers highly flexible, modular solutions that provide its clients with the ability to scale and reconfigure their automation equipment as their assays or technology changes. Visit www.highresbio.com or follow HighResBio on LinkedIn.
For further information please contact: sales@highresbio.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200124005116/en/
Contact information
Media Contact:
HighRes Biosolutions:
Brian O’Sullivan
VP Sales and Marketing
+1 781 932 1912 ext. 1201
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reintroducing Global Blue to Retailers and Shoppers Worldwide19.3.2024 15:19:00 EET | Press release
Taking shopping further through the power of experience Over 40 years ago, Global Blue pioneered the concept of Tax Free Shopping, changing the retail landscape and empowering international shoppers worldwide. Since then, its journey has evolved, now encompassing three families of solutions: Tax Free Shopping, Payments, and Post-Purchase Solutions. Within these industries, Global Blue consistently leverages its integrated software and data to bring value at every step of the journey and take shopping further. Driven by this commitment, Global Blue teams create engaging experiences that foster connections between consumers and brands while simplifying processes, to ensure every customer journey is seamless and intuitive. Through these efforts, Global Blue enables its clients to seize business opportunities, enhance customer loyalty, boost sales, and optimize operations and costs. “At Global Blue, we firmly believe that improving the shopping journey drives performance. This renewed focu
Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation19.3.2024 15:00:00 EET | Press release
Forge Biologics, a member of Ajinomoto Bio-Pharma Services and a leading manufacturer of genetic medicines, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), the healthcare regulatory body of the United Kingdom (UK), granted Innovation Passport designation to the Company’s novel AAV gene therapy program, FBX-101, to enter the Innovative Licensing and Access Pathway (ILAP). FBX-101 was created for the treatment of patients with Krabbe disease, a rare neurodegenerative disease that is usually fatal in untreated patients by age two. The ILAP is intended to accelerate regulatory and market access interactions in the UK. Maria Escolar, M.D., Forge’s Chief Medical Officer, will discuss the significance of achieving this regulatory designation and present a poster on updated data from REKLAIM, an early phase clinical trial for FBX-101, during the Advanced Therapies 2024 conference being held in London, March 19-20, 2024. “Considering the rapid progression of
SWISSto12 Continues Expansion, Growing Team by 25% and Adding New Production Space19.3.2024 15:00:00 EET | Press release
SWISSto12, one of Europe’s fastest growing aerospace companies and a leading satellite and Radio Frequency product manufacturer, announces its continued global expansion. The company has secured additional production space at its headquarters in Switzerland, increasing the size of its existing site to 5,700m2. In addition, SWISSto12 has welcomed several new Satcom engineering experts to its growing team, which has increased by 25% since the start of 2024 to over 125 employees working across its facilities in Switzerland, Europe and the USA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318493042/en/ HummingSat I-8 Inmarsat (Photo: Business Wire) SWISSto12 was recently named as one of the world’s “10 Hottest Satellite Companies.” This industry recognition follows the company’s announcement in Q4 2023 of securing over €200 million in customer orders for Radio Frequency subsystems and HummingSat satellites, including from l
Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up19.3.2024 15:00:00 EET | Press release
Mainstay Medical Holdings plc today announced the publication of the 5-year follow up from the ReActiv8-B randomized, sham-controlled, double-blinded trial. There were 126 patients who completed the 5-year follow up, and the published data clearly indicated that ReActiv8® Restorative Neurostimulation is a long-term, effective, durable, and safe therapy. ReActiv8 is the only restorative therapy for patients suffering from non-surgical, mechanical CLBP evidenced by multifidus dysfunction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319164677/en/ The long-term responses across pain, disability, and health-related quality of life measures are shown in the following graphs. (Graphic: Business Wire) The publication is available here: https://www.sciencedirect.com/science/article/pii/S1094715924000552 The ReActiv8-B study saw multiple patients have their implants removed for resolution of back pain. These removals for success
AngloGold Ashanti Releases Preliminary Unaudited Condensed Consolidated Financial Statements as of and for the Six Months and the Year Ended 31 December 202319.3.2024 14:04:00 EET | Press release
AngloGold Ashanti plc (“AngloGold Ashanti”, “AGA” or the “Company”) is pleased to provide its preliminary unaudited condensed consolidated financial statements as of and for the six months and the year ended 31 December 2023 (the “FY 2023 Earnings Release”). FY 2023 Financial and Operating Update The FY 2023 Earnings Release should be read together with AngloGold Ashanti’s preliminary financial update for the six months and the year ended 31 December 2023, which was published by the Company on 23 February 2024 (the “FY 2023 Preliminary Financial Update”). No changes have been made in the FY 2023 Earnings Release with respect to the production, cost or cash flow information included in the FY 2023 Preliminary Financial Update. The FY 2023 Preliminary Financial Update combined with the FY 2023 Earnings Release provide the Company’s financial and operating update for the six months and the year ended 31 December 2023. Announcement of Annual General Meeting Date The 2024 Annual General Mee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom